Xuezhi Hao

1.6k total citations
114 papers, 1.1k citations indexed

About

Xuezhi Hao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Xuezhi Hao has authored 114 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 86 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Xuezhi Hao's work include Lung Cancer Treatments and Mutations (91 papers), Lung Cancer Research Studies (54 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Xuezhi Hao is often cited by papers focused on Lung Cancer Treatments and Mutations (91 papers), Lung Cancer Research Studies (54 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Xuezhi Hao collaborates with scholars based in China, United States and Italy. Xuezhi Hao's co-authors include Junling Li, Puyuan Xing, Yan Wang, Xingsheng Hu, Yuxin Mu, Yutao Liu, Haiyan Xu, Ziyi Xu, Yuankai Shi and Shouzheng Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xuezhi Hao

111 papers receiving 1.1k citations

Peers

Xuezhi Hao
Erin Larkins United States
Yasir Y. Elamin United States
Fernando C. Santini United States
Agnese Montanino Italy
Francesca Mazzoni Italy
Reiko Kaji Japan
Youngjoo Lee South Korea
Paola Bordi Italy
Dengfeng Ren China
Jean-Louis Pujol France
Erin Larkins United States
Xuezhi Hao
Citations per year, relative to Xuezhi Hao Xuezhi Hao (= 1×) peers Erin Larkins

Countries citing papers authored by Xuezhi Hao

Since Specialization
Citations

This map shows the geographic impact of Xuezhi Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuezhi Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuezhi Hao more than expected).

Fields of papers citing papers by Xuezhi Hao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuezhi Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuezhi Hao. The network helps show where Xuezhi Hao may publish in the future.

Co-authorship network of co-authors of Xuezhi Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Xuezhi Hao. A scholar is included among the top collaborators of Xuezhi Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuezhi Hao. Xuezhi Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hao, Xuezhi, et al.. (2025). A Real‐World Study: Therapeutic Outcomes of ROS1‐Positive Advanced NSCLC. Thoracic Cancer. 16(9). e70086–e70086.
2.
3.
Xu, Ziyi, et al.. (2023). Adjuvant and neo‐adjuvant immunotherapy in resectable non‐small cell lung cancer (NSCLC): Current status and perspectives. SHILAP Revista de lepidopterología. 2(1). 65–78. 5 indexed citations
4.
Yang, Yaning, Guangjian Yang, Weihua Li, et al.. (2023). Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study. Thoracic Cancer. 14(33). 3275–3281. 5 indexed citations
5.
Xu, Haiyan, Yaning Yang, Fei Xu, et al.. (2023). Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer. Thoracic Cancer. 14(24). 2327–2337. 8 indexed citations
6.
Sun, Boyang, Tian Qiu, Jianchun Duan, et al.. (2023). Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors. Cancer Research Communications. 3(4). 532–539. 7 indexed citations
7.
Xu, Ziyi, Xuezhi Hao, Qi Wang, et al.. (2022). Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. SHILAP Revista de lepidopterología. 3 indexed citations
8.
Xu, Ziyi, Xuezhi Hao, Ke Yang, et al.. (2022). Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. Journal of Cancer Research and Clinical Oncology. 148(11). 3081–3089. 24 indexed citations
9.
Xie, Tongji, Yan Li, Fei Teng, et al.. (2022). Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC. Molecular Cancer Research. 21(4). 374–385. 2 indexed citations
10.
11.
Wang, Shouzheng, Jianming Ying, Yan Wang, et al.. (2021). Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic Cancer. 12(21). 2924–2932. 13 indexed citations
12.
Wang, Shouzheng, Tongji Xie, Xuezhi Hao, et al.. (2021). Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thoracic Cancer. 12(19). 2585–2593. 32 indexed citations
13.
14.
Huang, Li‐Ling, Xingsheng Hu, Yan Wang, et al.. (2021). Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients. Thoracic Cancer. 12(13). 1943–1951. 29 indexed citations
15.
Mu, Yuxin, Xuezhi Hao, Puyuan Xing, et al.. (2020). Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of Cancer Research and Clinical Oncology. 146(9). 2427–2433. 53 indexed citations
16.
Xing, Puyuan, Yuxin Mu, Xuezhi Hao, Y. Wang, & Junling Li. (2019). Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. Clinical & Translational Oncology. 21(10). 1424–1431. 20 indexed citations
17.
Wang, Shouzheng, Puyuan Xing, Ke Yang, et al.. (2019). Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic Cancer. 10(6). 1461–1468. 8 indexed citations
18.
Xing, Puyuan, Shouzheng Wang, Di Ma, et al.. (2019). Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. Targeted Oncology. 14(3). 325–333. 8 indexed citations
19.
Ma, Di, Yan Zhang, Puyuan Xing, et al.. (2019). Clinical features and outcomes ofALKrearranged non‐small cell lung cancer with primary resistance to crizotinib. Thoracic Cancer. 10(5). 1213–1219. 5 indexed citations
20.
Zhang, Xin, Puyuan Xing, Xuezhi Hao, & Junling Li. (2018). [Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer].. SHILAP Revista de lepidopterología. 21(5). 408–412. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erin Larkins Breakdown of academic impact, for papers by Yasir Y. Elamin Breakdown of academic impact, for papers by Fernando C. Santini Breakdown of academic impact, for papers by Agnese Montanino Breakdown of academic impact, for papers by Francesca Mazzoni Breakdown of academic impact, for papers by Reiko Kaji Breakdown of academic impact, for papers by Youngjoo Lee Breakdown of academic impact, for papers by Paola Bordi Breakdown of academic impact, for papers by Dengfeng Ren Breakdown of academic impact, for papers by Jean-Louis Pujol
Rankless by CCL
2026